Prostate Cancer: Metastatic Late Stage

Eligibility & Testing

The Oncotype DX AR-V7 Nucleus Detect test detects whether your tumor will be resistant to androgen receptor (AR)-targeted therapies, such as XTANDI® or ZYTIGA®.*  It can be performed whenever your doctor is considering AR-targeted therapies for your treatment.

You may be a candidate for the AR-V7 Nucleus Detect test if:

  • You have metastatic castration-resistant prostate cancer (mCRPC).
  • Your doctor is considering whether AR-targeted therapies are right for you.
  • You’ve already undergone AR-targeted therapies, and your doctor is deciding whether to continue those treatments or recommend other treatment options.

Because tumors can adapt (and become resistant) to AR-targeted therapies over time, your doctor may recommend the AR-V7 Nucleus Detect test after each round of AR-targeted therapy treatment.

Talking to your doctor about the test

When discussing the AR-V7 Nucleus Detect test, you may want to ask your doctor the following questions:

  • If I am a candidate for the AR-V7 Nucleus Detect test, how could we use the test results to develop my treatment plan?
  • What are my treatment options? What do you suggest for me and why?
  • What are the benefits of each treatment option? What are the drawbacks/side effects of each one?
  • How long do side effects of each treatment option last? Do they go away once treatment is complete?

*Xtandi® is a registered trademark of Astellas Pharma, Inc. Zytiga® is a registered trademark of Johnson and Johnson.

Stay in Touch

Have a specific question? Want to keep up with our latest news? We're here for you.

Contact Us
Making cancer care smarter.™
X

We may use cookies to improve your experience with our website and to provide you with more relevant content based on your interests. To learn more about what information we collect, how we use it, and how to manage cookies, review our Privacy Policy.